Bavarian Nordic A/S (BVNRY)

Market Cap	2.34B +24.1%
Revenue (ttm)	918.71M -4.4%
Net Income	181.05M -11.2%
EPS	2.29 -10.7%
Shares Out	n/a
PE Ratio	12.92
Forward PE	18.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,224
Average Volume	5,403
Open	10.30
Previous Close	10.10
Day's Range	10.16 - 10.30
52-Week Range	8.48 - 13.00
Beta	0.95
RSI	54.33
Earnings Date	May 13, 2026

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 1,861
• Stock Exchange: OTCMKTS
• Ticker Symbol: BVNRY

Financial Performance

In 2025, Bavarian Nordic's revenue was 6.24 billion, an increase of 9.23% compared to the previous year's 5.72 billion. Earnings were 1.38 billion, an increase of 39.21%.

Financial numbers in DKK